Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) has announced the launch of VisiRose, Inc., its first founded entity. VisiRose is a new clinical-stage biotechnology company focused on the commercialization of Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for the treatment of infectious keratitis and other serious eye infections. This therapy leverages Provectus’s bioactive synthetic small molecule, Rose Bengal Sodium (RBS), as its active pharmaceutical ingredient.
The University of Miami, a key partner, holds a minority equity stake in VisiRose.
RB PDAT is an innovative, non-invasive investigational treatment for ocular infections, developed from pioneering research at the Ophthalmic Biophysics Center (OBC) at Bascom Palmer Eye Institute (BPEI) of the University of Miami’s Miller School of Medicine. The therapy combines Provectus’s pharmaceutical-grade RBS API with OBC’s proprietary light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Dominic Rodrigues, Acting CEO of VisiRose and President of Provectus, emphasized the significance of RB PDAT, stating, “RB PDAT represents a groundbreaking solution for patients at risk of vision loss from infectious keratitis. We believe this therapy’s targeted infection-fighting capabilities and vision-preserving benefits will provide hope for those affected by this debilitating condition.”
Ed Pershing, Chairman of VisiRose and Provectus, highlighted the strategic value of VisiRose’s launch, noting, “VisiRose exemplifies Provectus’s forward-thinking business model by bridging innovation with real-world impact. This clinical-stage, ophthalmology-focused entity enables us to better address unmet medical needs and unlock value for our stockholders, particularly within the rapidly growing eye care sector.”
About VisiRose
VisiRose is a newly launched clinical-stage biotechnology company, created through a collaboration between Provectus Biopharmaceuticals and the University of Miami. The company aims to commercialize cutting-edge ocular research from the Miller School of Medicine’s Bascom Palmer Eye Institute, using Provectus’s bioactive synthetic small molecule, Rose Bengal Sodium (RBS). For more details, visit visirose.com.
About Bascom Palmer Eye Institute
Bascom Palmer Eye Institute, the ophthalmology department of the University of Miami Miller School of Medicine, is a leader in advancing eye care and research. Ranked as the nation’s top ophthalmology center for 2024-2025 by U.S. News & World Report, Bascom Palmer has received the No. 1 ranking for 21 consecutive years, marking a legacy of excellence in improving vision and preventing blindness.
About Provectus
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapies based on halogenated xanthene molecules. Its lead drug candidate, Rose Bengal Sodium (RBS), is the cornerstone of the company’s platform aimed at treating various serious conditions, including cancer and eye infections.
Related topic:
ODORBN Advocates for Stronger Eye Care Standards in Nigeria
Alcon Marks First Anniversary of African Phaco Program
Ophthalmologists in Himachal Pradesh Raise the Bar for Eye Care Services
